Study on diabetes drug Avandia

GlaxoSmithKline finally got some good news from a study of its diabetes drug Avandia, but some top leading cardiologists remain unconvinced, saying the company’s new research has serious flaws.

The results, unveiled late this afternoon at the American Diabetes Association conference in New Orleans, found Avandia doesn’t increase patients’ risk for heart attacks, according to a report from Jared A. Favole of Dow Jones Newswires and WSJ’s Alicia Mundy. The new findings, contained in a study called Record, contrast about 10 other studies, including some by Glaxo, and a key analysis in 2007 that raised serious questions about its safety.

It's good to hear that avandia doesn't increase a patient's risk for heart attacks but if you have one study that's in favor and ten that aren't, I think that the overwhelming evidence is still that it could cause heart attacks. Unless they perhaps found something methodologically unsound with the previous attempts? Is that the case?